Device Trial Radar · NCT07043036
Randomized Controlled Trial Comparing Remote Patient Monitoring vs Standard Care in IBD Patients Initiating or Changing Advanced Therapy
Last checked: Nov 20, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
Jun 2025
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- ResilienceNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Sanoia
- First posted
- Jun 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial aims to evaluate whether GutyCare, a digital remote patient monitoring (RPM) solution, can enhance organizational outcomes while maintaining non-inferior clinical results in patients with inflammatory bowel disease (IBD) who are initiating or undergoing significant modifications in advanced therapy. The study compares standard care to an intervention involving the use of GutyCare, a mobile application that collects patient-reported outcomes related to symptoms. When clinically significant symptoms are identified, alerts are transmitted to the care team, facilitating timely and personalized therapeutic adjustments.
Conditions
- IBD
Interventions
GutyCareDevice
Device : GutyCare The participants will use GutyCare remote patient monitoring.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of on-site IBD-related visitsTime frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.